title: Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.
authors.affiliation: Division of Medical Oncology, Johns Hopkins Oncology Center (Mid-Atlantic Oncology Program and Southwest Oncology Group), Baltimore, MD 21287-8936.
authors.forename: M A
authors.initials: MA
authors.lastname: Eisenberger
authors.forename: E D
authors.initials: ED
authors.lastname: Crawford
authors.forename: M
authors.initials: M
authors.lastname: Wolf
authors.forename: B
authors.initials: B
authors.lastname: Blumenstein
authors.forename: D G
authors.initials: DG
authors.lastname: McLeod
authors.forename: R
authors.initials: R
authors.lastname: Benson
authors.forename: F A
authors.initials: FA
authors.lastname: Dorr
authors.forename: M
authors.initials: M
authors.lastname: Benson
authors.forename: J T
authors.initials: JT
authors.lastname: Spaulding
mesh_terms: D002986:Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D011379:Prognosis; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D012044:Regression Analysis; D016019:Survival Analysis